Emergent BioSolutions 4Q Revenues: $98.1 million (+4%) 4Q Earnings: $15.2 million (-6%) FY Revenues: $312.7 million (+11%) FY Earnings: $31.1 million (+32%) Comments: For the year, product sales were $257.9 million, up 19%, driven by the biodefense business with strong performance reflected by the increased BioThrax doses shipped and sales of newly acquired medical countermeasure RSDL. Contracts and grants revenues were $54.8 million, down 17% primarily due to decreased revenue associated w...